News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

PDF 302 KB
Berlin (Germany) and Germantown, MD (U.S.A.) – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that the Company will receive an EU grant under the industrial leadership Horizon 2020 research and innovation program for SME (Small and Medium-Sized Enterprises). The grant duration is expected to be 24 months with a total fund volume of up to EUR 2.77 million.

The grant will fund the clinical research to validate Epigenomics’ proprietary lung cancer biomarkers with the goal to develop a CE-marked product for the detection of lung cancer in blood plasma under the new in-vitro diagnostic directive.

“We are proud, that our lung cancer grant application has received the favor of the Horizon 2020 program”, said Dr. Uwe Staub, COO of Epigenomics. “With our Epi proLung® test we have already proven that new and innovative diagnostic tests can make a difference in the detection of lung cancer. With this new project, we will clinically validate a novel CE-marked diagnostic product that can detect lung cancer in blood plasma at an early stage and has a variety of possible future clinical applications in the diagnosis of lung cancer.”

The EU commission informed Epigenomics that the grant proposal has been favorably evaluated and that the agency wishes to proceed with the grant agreement. In a next step the grant agreement preparation and the internal completion of the formal selection process will be concluded.

About Horizon 2020

Horizon 2020 is the EU Framework Program for Research and Innovation and the largest EU program ever in this field with nearly EUR 80 billion of funding available over 7 years (2014 to 2020). It represents a flagship initiative aimed at securing global competitiveness, economic growth and job creation in Europe through the promotion of innovation and research. Horizon 2020 is divided into three sections. The pillar “industrial leadership” aims to speed up development of the technologies and innovations that will underpin tomorrow’s businesses and help innovative European SMEs to grow into world-leading companies.

About Epigenomics

Epigenomics ( is a molecular diagnostics company developing and commercializing innovative products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe, has received approval by the Chinese Food and Drug Administration for China and is under regulatory review by the U.S. Food and Drug Administration (FDA). Additionally, the Company markets its tissue assay for use in lung cancer diagnosis, Epi proLung®, in Europe. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies and testing laboratories. Epigenomics is an international company with operations in Europe and the U.S.A.

Contact Epigenomics AG

Antje Zeise, Manager IR | PR
Epigenomics AG
Geneststraße 5
10829 Berlin
Phone +49 (0) 30 24345 386

For US press inquiries:

Epigenomics, Inc.
20271 Goldenrod Lane, Suite 2027
Germantown, Maryland 20876

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.